TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01135563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine and Sirolimus
Description: Patients will be enrolled to receive vinblastine and sirolimus in 28 day cycles. Using the 3+3 standard Phase1 design, vinblastine will be administered via IV push on Days 1, 8, 15, 22. The starting dose of 4 mg/m2 (Dose Level 1) is 67% of the established MTD (6 mg/m2) for this schedule in pediatrics. Dose escalation will take place in a standard 3+3 design, in which doses will increase by approximately 20 to 25% in successive 3-patient cohorts.~Sirolimus (rapamycin) will be given by mouth (tablet or suspension) once daily throughout the cycle. Ideally patients will remain on the same dose form (tablet or suspension) for the duration of the study. All patients will be assigned a target sirolimus serum trough
Study: NCT04541277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab combined with DNA demethylation agent +/- CAG regimen
Study: NCT00705744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic acid (Dermacyd Femina)
Study: NCT01375855

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous transluminal Coronary Angioplasty
Description: Coronary artery stent implantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous transluminal Coronary Angioplasty
Description: Coronary artery stent implantation
Study: NCT03618589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Patients in the pregabalin add-on group received 75mg of pregabalin twice a day for the first week (150 mg/day) and 150mg of pregabalin twice a day (300 mg/day) for the second week and 300mg of pregabalin twice a day (600mg/day) for subsequent 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Opioid
Description: Patients in the opioid group received the only opioid (5mg of oxycodone three times a day) for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid
Description: Patients in the opioid group received the only opioid (5mg of oxycodone three times a day) for 8 weeks.
Study: NCT05288907

Intervention type: DRUG
Intervention: Lidocaine Ointment
Description: Composite over-the-counter lidocaine ointment administered twice daily for 2 weeks.
Study: NCT02805504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: This group will receive intraoperative local Liposomal Bupivacaine injection at the surgical site.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine
Description: This group will receive intraoperative Bupivacaine HCl injection at the surgical site.
Study: NCT02395302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Action Pneumatic Compression
Description: Wear in sustained mode for 14 hours and pneumatic compression mode for 3 hours during the 4 week treatment period.
Study: NCT03400956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: Orally, coated tablet 2 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: Orally, coated tablet 2 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: Orally, coated tablet 2 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Orally, coated tablet, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Orally, coated tablet, once daily
Study: NCT02251964

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab
Description: 2 times 1000mg dose at 14 days interval treatment

Intervention type: RADIATION
Group type: OTHER
Intervention: Zr-89-rituximab immuno PET/CT
Description: Immuno labeled PET/CT of the lungs
Study: NCT01589770

Intervention type: OTHER
Group type: OTHER
Intervention: cardiac Magnetic Resonance imaging

Intervention type: OTHER
Group type: OTHER
Intervention: cardiac Magnetic Resonance imaging
Study: NCT03511898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-149 dose level 1
Description: single intravitreal injection of THR-149 dose level 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-149 dose level 2
Description: single intravitreal injection of THR-149 dose level 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-149 dose level 3
Description: single intravitreal injection of THR-149 dose level 3
Study: NCT01685333

Intervention type: DRUG
Group type: OTHER
Intervention: Epoetin Alfa
Description: Intravenous single-dose administration of 100 IU/kg of the test drug (Human Recombinant Epoetin) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.

Intervention type: DRUG
Group type: OTHER
Intervention: Epoetin Alfa
Description: Intravenous single-dose administration of 100 IU/kg of the test drug (Human Recombinant Epoetin) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
Study: NCT03105466

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep anterior lamellar keratoplasty
Description: Deep anterior lamellar keratoplasty using acellular porcine cornea; 0.05%Tacrolimus eye drops, four times a day for at least one year; 0.3% Tobradex eyedrops, four times-one times a day for one year.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acellular Porcine Cornea

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobradex eyedrops
Study: NCT04440423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clotiazepam 5 mg Test Product Coated Tablets
Description: Investigational Medicinal Product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotiazepam 5 mg Reference Product Coated Tablets
Description: Rize (Trademark)
Study: NCT03227809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Handbook condition
Description: Parents of first-year university students receive parent handbook summer before start of university. Handbook contains suggestions for activities and conversations parents can conduct with students.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Handbook plus condition
Description: Parents of first-year university students receive parent handbook summer before start of university. Handbook contains suggestions for activities and conversations parents can conduct with students. Parent also receive text messages throughout the year.
Study: NCT01642628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Education
Description: Patients allocated to the experimental group will be given a small hand-held mirror and structured mirror viewing education verbally. In addition, they will receive a mirror viewing handout. This intervention will be given prior to mastectomy surgery. In addition, participants will receive all other standard care.
Study: NCT02819908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imprimis Dropless
Description: Tri-Moxi-Vanc transzonular intravitreal injection
Study: NCT04581720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Train-of-four (TOF)
Description: Give 4 electrical stimulants on the ulnar nerve to see if the 4 responses (T1 \~ T4) of adductor pollicis fade or not. If there's no neuromuscular block, it shows no fade, or it fades. When an operation is over under general anesthesia, we use the ratio of the height of T4 to T1, and the ratio is over 90%, the neuromuscular block is recovered enough to extubation.
Study: NCT02819908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imprimis Less Drops
Description: Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively
Study: NCT03493932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: OPDIVO is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
Study: NCT01276184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Text Message
Description: Women in the SMS Text Message group that reschedule a vaccination visit will receive text message reminders one per day for each of the seven days prior to the rescheduled visit (or as many days as possible depending on when the rescheduled visit will take place - for example, if they call in and reschedule the visit to take place in 4 days, they will receive text messages for the 3 days prior to the rescheduled visit). Participants in both the Usual Care group and the SMS Text Message group will receive the standard reminder from the clinic for their re-scheduled appointment(s).
Study: NCT03241446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilmanocept
Description: Intravenously administered Technetium Tc 99m tilmanocept
Study: NCT03493932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986016
Description: Anti-Lymphocyte Activation Gene-3 antibody undergoing clinical evaluation by Bristol-Myers Squibb
Study: NCT03619967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multispectral imager
Description: Device: Bio-inspired multispectral imager~-Manufactured at University of Illinois at Urbana Champaign
Study: NCT00243646

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiation
Description: All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant
Study: NCT03241446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilmanocept
Description: Intravenously administered Technetium Tc 99m tilmanocept

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilmanocept
Description: Intravenously administered Technetium Tc 99m tilmanocept
Study: NCT01349140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKY0402
Description: Single-injection femoral nerve block. Initial doses of SKY0402 will begin at 0 mg, and 2 mg (high) for the first subject; and 1 mg (low) and 3 mg (high) for the second subject. The next doses will be between 0-80 mg per side, determined prior to randomization of each subsequent subject. The specific subsequent doses will increase, remain the same, or decrease, determined by the P.I. in consultation with the manufacturer of SKY0402. Doses will always remain within the range of 0-80 mg per side, for a total possible dose of 0-160 mg.
Study: NCT00474240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEGR-733 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEGR-733 10 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEGR-733 5 mg + atorvastatin 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEGR-733 10 mg + atorvastatin 20 mg
Study: NCT02673333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study: NCT03216460

Intervention type: DEVICE
Group type: OTHER
Intervention: Insulet automated glucose control system
Description: Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4Share® AP System and personalized model predictive control algorithm.
Study: NCT00243646

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiation
Description: All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lupron
Description: 9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
Study: NCT00887458

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole 200 mg
Description: Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole 300mg
Description: Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
Study: NCT03437421

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: * Patients with 29≤ 25-OH-D3 ≥20 ng/mL will receive 200 000 UI orally the first month (100 000 UI at T0 + 100 000 UI at T0+15 days, UVEDOSE™ Laboratoires Crinex, Montrouge, France) followed for the last 2 months by one daily dose (5 drops orally = 1 000 UI/day, DÉDROGYL™ , DB Pharma, La Varenne-Saint-Hilaire, France).~* Patients with : 19≤ 25-OH-D3 ≥10 ng/mL will receive orally 300 000 UI (100 000 UI at T0 + 100 000 UI at T0+23days + 100 000 UI at T0+45days; UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™ ).~* Patients with : 25-OH-D3 \<10 ng/mL will receive orally 400 000 UI (100 000 UI at T0 + 100 000 UI at T0+15days + 100 000 UI at T0+30 days + 100 000 UI at T0+45days, UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: * Patients with 29≤ 25-OH-D3 ≥20 ng/mL will receive 200 000 UI orally the first month (100 000 UI at T0 + 100 000 UI at T0+15 days, UVEDOSE™ Laboratoires Crinex, Montrouge, France) followed for the last 2 months by one daily dose (5 drops orally = 1 000 UI/day, DÉDROGYL™ , DB Pharma, La Varenne-Saint-Hilaire, France).~* Patients with : 19≤ 25-OH-D3 ≥10 ng/mL will receive orally 300 000 UI (100 000 UI at T0 + 100 000 UI at T0+23days + 100 000 UI at T0+45days; UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™ ).~* Patients with : 25-OH-D3 \<10 ng/mL will receive orally 400 000 UI (100 000 UI at T0 + 100 000 UI at T0+15days + 100 000 UI at T0+30 days + 100 000 UI at T0+45days, UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™).
Study: NCT02392260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vasculight
Description: Comparative measre of Pulse Wave velocity with both Vasculight prototype and Echocardiographic machine.
Study: NCT02504255

Intervention type: BIOLOGICAL
Intervention: Biological samplings
Description: Blood, urine and faecal sampling every 3 months

Intervention type: OTHER
Intervention: Questionnaires
Description: patients fill several questionnaires every month to assess stress and adaptation parameters
Study: NCT01486420

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injections
Description: Corticosteroid injections in and around A1-pulley.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery
Description: Open A1-pulley release
Study: NCT02318784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Study: NCT03431233

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-enriched bar, commercial cereal bar, or water
Description: Protein enriched bar, commercial cereal bar, or water will be provided 15 minutes before breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-enriched bar, commercial cereal bar, or water
Description: Protein enriched bar, commercial cereal bar, or water will be provided 15 minutes before breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-enriched bar, commercial cereal bar, or water
Description: Protein enriched bar, commercial cereal bar, or water will be provided 15 minutes before breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-enriched bar, commercial cereal bar, or water
Description: Protein enriched bar, commercial cereal bar, or water will be provided 15 minutes before breakfast.
Study: NCT00243646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Casodex
Description: 9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
Study: NCT00043550

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Expressive Therapy
Description: The aim of supportive-expressive psychotherapy is to help patients understand the causes of relationship conflicts in the context of a supportive relationship.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Participants will receive sertraline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pill Placebo
Description: Participants will receive a pill placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Participants will receive venlafaxine.
Study: NCT03259620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS006
Description: Furosemide Topical Gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS006 Vehicle
Description: Vehicle Topical Gel
Study: NCT03635411

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside and Pterostilbene
Description: Nicotinamide riboside and pterostilbene manufactured by Basis

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Basis supplement.
Study: NCT01151943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane (TAP) Block
Description: Bilateral injection of levobupivacaine (20 mL, 3.75 mg/mL)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incisional Infiltration of Local Anesthetic
Description: continuous administration of levobupivacaine (1,25 mg/mL,5 mL/h) during 48 hours.
Study: NCT02907190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bean Type
Description: 1/2 cup of freshly boiled beans will be eaten by participants on separate study visits

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Starchy Foods
Description: 1/2 cup serving of one of 4 starchy foods will be eaten by participants on different study visit
Study: NCT04926402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo Care Education Program
Description: It is a special method of caring for a premature infant in which the baby is positioned for at least 1 hour a day in an upright skin-to-skin and chest-to-chest contact with its mother.
Study: NCT03579602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tozuleristide
Description: Tozuleristide will be administered at least 1 hour and no more than 36 hours prior to planned surgical excision of their tumor.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Canvas System
Description: All subjects enrolled in the study will have their tissue imaged with the Canvas System.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Canvas System
Description: All subjects enrolled in the study will have their tissue imaged with the Canvas System.
Study: NCT00492063

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell culture-derived trivalent subunit influenza vaccine (cTIV)
Description: One vaccination (0.5 mL) of cell culture-derived influenza vaccine (cTIV) was administered in the deltoid muscle

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Egg-derived trivalent subunit influenza vaccine (TIV)
Description: One vaccination (0.5 mL) of egg-derived influenza virus vaccine (TIV) was administered in the deltoid muscle
Study: NCT05365945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NDT Bobath therapy
Description: Their physiotherapy was based on exercises that heavily employed the core muscles to equalize tension and strength, according to the NDT Bobath concept. The duration of the treatment session for each patient in both groups was 120 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The classic exercises.
Description: They underwent classical neurological rehabilitation. such as passive exercises, but also an approximation. In addition, the patients performed self-assisted exercises on a manual rotor, and in order to relieve the directly affected limb, the patients exercised in a suspension system. As the physiotherapy progressed, the patients performed active exercises, and then active exercises with resistance, e.g. using the Thera Band. Patients also exercised their balance with the use of large gymnastic balls or sensor pads. A large part of the physiotherapy was locomotion training and gait re-education.~The duration of the treatment session for each patient in both groups was 120 minutes.
Study: NCT03478865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A palmitate
Description: Provide vitamin A to participants with pre/post assessments of vision.
Study: NCT03982862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 0.1ml 2% Xylocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Description: 4U Botox® diluted to 0.1 ml
Study: NCT02776202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine monophosphate
Description: The HSCT preparative regimen will consist of~* Thymoglobulin: 2.5 mg /kg/day intravenously (IV) on Days -8 through -5~* Fludarabine: 35 mg/m2/day IV on Days -8 through -4~* Melphalan: 140 mg/m2 IV on Day -3~* Rest on Day -2 and -1~* Day 0 is the day of transplant~* GVHD prophylaxis: sirolimus beginning on Day -1 for at least one year and mycophenolate mofetil (MMF) from Day -3 to +45 or to 7 days after neutrophil engraftment, whichever is later.
Study: NCT04008927

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HCV screening
Description: All patients will have HCV screening using rapid tests. HIV and HBV testing will also be conducted and patients will be appropriately referred to appropriate health services.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnosis of hepatitis C
Description: HCV-RNA assay (GeneXpert, Cepheid) will be performed for all participants with positive HCV serology to determine if patients have chronic hepatitis C (defined by HCV-RNA\>10 UI/mL). In addition a measure of the liver stiffness will be performed.

Intervention type: DRUG
Group type: OTHER
Intervention: HCV treatment
Description: Direct-Acting Antiviral drugs will be prescribed for 8 or 12 weeks according to liver assessment.
Study: NCT04803682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive Intervention
Description: Participate in ASPIRE and mentorship program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies (pre and post questionnaire)